CIP2A is also a key mediator of erlotinib-induced apoptosis in EGFR–wild-type NSCLC [26], and modulation of CIP2A by bortezomib can overcome erlotinib resistance [27]. The gene discussed is CIP2A; the disease is non-small cell lung carcinoma.